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Background: Emerging evidence has shown that microRNAs are involved in gastric cancer development and
progression. Here we examine the role of miR-133b in gastric cancer.
Methods: Quantitative real-time PCR analysis was performed in 140 patient gastric cancer tissues and 8 gastric
cancer cell lines. The effects of miR-133b in gastric cancer cells metastasis were examined by scratch assay, transwell
migration and matrigel invasion. In vivo effects of miR-133b were examined in an intraperitoneal mouse tumor
model. Targets of miR-133b were predicted by bioinformatics tools and validated by luciferase reporter analyses,
western blot, and quantitative real-time PCR.
Results: MiR-133b was significantly downregulated in 70% (98/140) of gastric cancer patients. Expression of
miR-133b was negatively correlated with lymph node metastasis of gastric cancer in patients. Similarly, the
expression of miR-133b was significantly lower in seven tested gastric cancer cell lines than in the immortalized
non-cancerous GES-1 gastric epithelial cells. Overexpression of miR-133b markedly inhibited metastasis of gastric
cancer cells in vitro and in vivo. Moreover, the transcriptional factor Gli1 was identified as a direct target for
miR-133b. Level of Gli1 protein but not mRNA was decreased by miR-133b. Activity of luciferase with Gli1
3′-untranslated region was markedly decreased by miR-133b in gastric cancer cells. Gli1 target genes, OPN and
Zeb2, were also inhibited by miR133b.
Conclusions: MiR-133b is frequently decreased in gastric cancer. Overexpression of miR-133b inhibits cell metastasis
in vitro and in vivo partly by directly suppressing expression of Gli1 protein. These results suggested that miR-133b
plays an important role in gastric cancer metastasis.
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Based on the GLOBOCAN 2008 estimates, a total of
989,600 new gastric cancer (GC) cases and 738,000
deaths occurred in 2008, accounting for 8% of the total
cancer cases and 10% of total cancer deaths worldwide
[1]. Despite advances in treatment, the survival rate of
patients with GC remains low. There is still a vital need
for the development of novel diagnostic and therapeutic
strategies for this disease.* Correspondence: byliu@sjtu.edu.cn; zhuzg@shsmu.edu.cn
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reproduction in any medium, provided the orMicroRNAs (miRNAs) are a class of small (18–25 nu-
cleotides), endogenous, non-coding RNAs that silence
protein expression by interacting with the 3′-untranslated
regions (3′UTRs) of target mRNAs. Growing evidence has
shown that miRNAs can function as either oncogenes or
tumor suppressors in various cancers [2,3]. Several studies
have demonstrated that miRNAs play an important role in
GC [4,5]. In our previous work, we identified numerous
putative miRNAs with different expression levels in GC
and normal tissues by comparing the miRNA expression
profile of 28 patient samples of GC tissues and adjacent
non-tumor tissues [6]. We have confirmed and inves-
tigated several miRNAs disregulated in GC, such as
miR-126 [7], miR-409-3p [8], miR-625 [9], miR-21 [10],td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been identified in association with GC, the mechan-
ism of miRNAs in gastric tumorigenesis still needs to be
investigated. MiR-133b was one of the most significantly
downregulated miRNAs in GC; however it has been rarely
investigated in GC. These results were consistent with
another group’s finding from miRNA microarray data in
three GC patient tissues [13]. MiR-133b was originally
suggested as being solely expressed in skeletal muscle
[14]. Recently, miR-133b was implicated to function as a
tumor suppressor and its levels were decreased in many
types of cancers such as head and neck/oral, bladder,
non-small cell lung, cervical, colorectal and esophageal
squamous cell cancer [15-22].
In this study, we found that the expression of miR-133b
was downregulated in 70% (98/140) of the GC tissues, and
this downregulation was associated with lymphatic metas-
tasis of GC. We also present the first data demonstrating
that miR-133b overexpression could repress the metastasis
of GC cells in vitro and in vivo by directly targeting the
Gli1 transcription factor and inhibiting expression of the
Gli1 target genes OPN and Zeb2.
Methods
Ethics statement
Written informed consent was obtained from all partici-
pants. The study was approved by the Human Research
Ethics Committee of Ruijin Hospital, School of Medicine,
Shanghai Jiao Tong University (HREC 08–028), and the
Laboratory Animal Ethics Committee of Ruijin Hospital.
Research in human GC tissues was conducted in accord-
ance with the Declaration of Helsinki. Animal procedures
were carried out according to the Animal Research: Report-
ing In Vivo Experiments (ARRIVE) guidelines.
Cell lines and cell culture
Human GC cell lines SGC-7901, NCI-N87, BGC-823, and
AGS were purchased from Shanghai Institutes for Bio-
logical Sciences, Chinese Academy of Sciences (Shanghai,
China). MKN-45 and MKN-28 were obtained from the
Japanese Cancer Research Resources Bank (Tokyo, Japan),
and KATO III and SNU-1 were originally purchased from
the American Type Culture Collection (Manassas, VA,
USA). GES-1, an immortalized gastric epithelial cell
line, was a gift from Professor Feng Bi (Huaxi Hospital,
Sichuan University, Chengdu, China). Cells were stored,
recovered from cryopreservation in liquid nitrogen and
used at early passages. All cells were maintained in RPMI-
1640 medium plus 10% fetal bovine serum (FBS) and
cultured in a 5% CO2 humidified atmosphere.
Patient tissues
GC patient tissues and the adjacent non-tumor tissues
were obtained from 140 GC patients undergoing radicalgastrectomy at the Department of Surgery, Ruijin Hos-
pital, School of Medicine, Shanghai Jiao Tong University.
All patients provided consent and samples were con-
firmed by independent pathological examination. None
of the patients received preoperative treatment. The
pathologic tumor staging was determined according to
the International Union Against Cancer (2009).
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated with Trizol reagent (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s in-
structions. After the quantitation of mRNA, 2 μg of total
RNA were reverse transcribed with random primers fol-
lowing the manufacturer’s instructions (MBI Fermentas,
Vilnius, Lithuania). The PCR amplifications were perfor-
med in triplicate using the SYBR Green Real Time PCR
(Applied Biosystems, Foster City, CA, USA) following the
manufacturer’s instructions. Quantification was performed
using the ΔΔCt relative quantification method with
human GAPDH as an internal control. The following
primers were used: Gli1 [GenBank:NM_005269.2, GI:
224809486] (sense: 5′-GGA AGT CAT ACT CAC GCC
TCG A-3′; antisense: 5′-CAT TGC TGA AGG CTT TAC
TGC A-3′) [23], Zeb2 [GenBank: NM_001171653.1, GI:
224809486] (sense: 5′-AGC CAC GAT CCA GAC CGC
AA-3′; antisense: 5′- GCT GTG TCA CTG CGC TGA
AGG T-3′), OPN [Genbank: NM_000582, GI:38146097]
(sense: 5′-GGA TCC CTC ACT ACC ATG AG-3′; anti-
sense: 5′-AAG CTT GAC CTC AGA AGA TGC ACT-3′)
[24] and GAPDH [GenBank:NM_002046.4, GI: 284413745]
(sense: 5′-GGA CCT GAC CTG CCG TCT AG-3′; anti-
sense: 5′-GTA GCC CAG GAT GCC CTT GA-3′).
The expression levels of miRNAs were assessed by the
stem-loop RT-PCR method using the Hairpin-it™ miR-
NAs qPCR Quantitation Kit (GenePharma, Shanghai,
China) with specific primers for miR-133b and U6 small
nuclear RNA (RNU6B). Relative miRNA expression of
miR-133b was normalized against the endogenous
control, U6, using the ΔΔCt method.
Transient transfection of miRNA mimics
MiR-133b mimic (dsRNA oligonucleotides) and negative
control mimic (NC) (sense: 5′-UUC UCC GAA CGU
GUC ACG UTT-3′, antisense: 5′-ACG UGA CAC GUU
CGG AGA ATT-3′) were purchased from GenePharma
(Shanghai, China). Transfection was carried out using
Lipofectamine™ 2000 (Invitrogen) according to the man-
ufacturer’s procedures. MiRNA mimics were used at a
final concentration of 100 nM.
Scratch assay
At 16 h post-transfection with miRNA mimics, cells
(1 × 106 cells/well) were seeded to 90% confluence in a
6-well plate for overnight culture. A scratch was made
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ing an open “wound” that was clear of cells. The dis-
lodged cells were removed by three washes with culture
media. Plates were then cultured with serum-reduced
medium containing 1% FBS. Migration into the open
area was documented at 72 h post-scratching. Each condi-
tion was tested in triplicate and each experiment was
repeated at least three times.
Cell migration and invasion assays
At 16 h post-transfection with miRNA mimics, 5 × 104
cells in serum-free medium were introduced into the
upper compartment of the BD BioCoat control inserts
(Cat. # 354578, BD Discovery Labware, Bedford, MA,
USA) fitted with membranes of 8 micron porosity sepa-
rating the upper and lower compartments. The lower
compartment was filled with normal culture medium sup-
plemented with 10% FBS as the chemoattractant. Cells
were incubated for 48 h for the migration assay and 72 h
for the invasion assay. For the invasion assay, the inserts
were previously coated with extracellular matrix gel (BD
Biosciences, Bedford, MA, USA). At the end of the experi-
ments, the cells on the upper surface of the membrane
were removed, and the cells on the lower surface were
fixed and stained with 0.2% crystal violet. Five visual fields
of each insert were randomly chosen and counted under a
light microscope. Each condition was assayed in triplicate
and each experiment was repeated at least three times.
Construction of the reporter gene system and luciferase
activity assay
The 203 bp full length wild-type (WT) Gli1-3′UTR
containing the putative miR-133b binding site or mutant
Gli1-3′UTR (mut) was synthesized (Sangon, Shanghai,
China). After digestion by SpeI and HindIII, the frag-
ments of wild-type and mutant Gli1-3′UTR were cloned
into the SpeI and HindIII sites of the pMIR-Report lucif-
erase vector (Applied Biosystems) and named pMIR/
Gli1 and pMIR/Gli1/mut, respectively. Sequencing was
used to verify the constructs.
For the relative luciferase reporter assay, cells were
seeded in a 24-well Plate 24 h prior to assay performance.
In each well, 100 ng pMIR/Gli1 or pMIR/Gli1/mut, 1 ng
pRL-TK (Promega, Madison, WI, USA) containing Renilla
luciferase and 100 nM miRNA mimics were cotransfected
using Lipofectamine™ 2000 reagent. Relative luciferase
activity was calculated 48 h after cotransfection using the
Dual-Glo Luciferase assay (Promega) according to the
manufacturer’s procedure. Firefly luciferase activity was
normalized to Renilla luciferase activity.
Western blot analysis
Protein levels were quantified by standard western blot
procedures with the following antibodies: Gli1 (1:1000,Cell Signaling Technology, Beverly, Massachusetts, USA),
OPN (1:500, IBL, Japan), Zeb2 (1:1000, Prosci, Poway, CA,
USA) and GAPDH (1:20000, Abcam, Cambridge, UK).
Protein levels were normalized to total GAPDH levels.
Retroviral transfection for stable cell lines
As previously described [8], retroviruses containing miR-
133b or no insert (NC, negative control) were produced.
After infections of MKN-28 cells, positive cells were
selected and named RV-miR-133b and RV-miR-NC.
MiR-133b expression was confirmed by qRT-PCR.
In vivo metastasis peritoneal spreading assay
MKN-28, RV-miR-NC and RV-miR-133b cells were resus-
pended and injected intraperitoneally (2 × 106 cells/mouse)
into 4-week-old male BALB/C nude mice (Shanghai
Laboratory Animal Center of China). Ten mice were in-
cluded in each group. On the 60th day after intraperitoneal
injection, mice were euthanized by cervical dislocation,
and peritoneal spreading of tumor lesions was assessed by
necropsy. All experiments were performed in accordance
with the official recommendations of the Chinese Animal
Committee.
Statistical analysis
All tests of significance were two tailed. Continuous
variables were compared using the Student’s t test for
normally distributed variables and Wilcoxon rank-sum
test for non-normally distributed variables. The relation-
ship between the miR-133b expression levels and clini-
copathologic parameters was analyzed using tertiles and
the Pearson Chi-square test. All values are presented as
mean ± SD. All statistical analyses were performed using
PASW Statistics 18.0 software (IBM, Chicago, IL, USA).
p <0.05 was considered to indicate a statistically signifi-
cant result.
Results
The expression of miR-133b is downregulated in GC
Previous microarray results suggested that miR-133b
was significantly downregulated in GC [6]. To confirm
the microarray results, we examined paired tumor and
adjacent non-tumor gastric tissues from 140 GC patients
using qRT-PCR analysis. Expression of miR-133b was
significantly downregulated in tumor tissues compared
with matched non-tumor tissues in 70% (98/140) of the
GC patients (p < 0.001) (Figure 1A, B). Cellular experi-
ments found similar results, showing that expression of
miR-133b was much lower in the seven tested GC cell
lines than in the immortalized normal gastric mucosal
epithelial cell line GES-1 (Figure 1C). Together these
results provide strong evidence that miR-133b is markedly
downregulated in GC.
Figure 1 MiR-133b is downregulated in GC tissues and cells. (A) Relative expression of miR-133b in 140 GC patient tissues compared with
adjacent non-tumor tissues. qRT-PCR results are shown as -△△CT values. (B) The boxes represent the distribution of miR-133b expression from the
25the to 75th percentiles of all patient samples. The whiskers represent distribution from the 10th to 90th percentiles, with the horizontal lines
showing the median levels of miR-133b. ***, p <0.001. (C) Relative expression of miR-133b in eight GC cell lines and one immortalized normal
gastric mucosal epithelial cell line (GES-1). qRT-PCR results are the mean of three independent experiments ± S.D. *, p <0.05, **, p <0.01.
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of miR-133b and clinicopathologic features in GC, the
clinical and pathologic characteristics of the 140 GC
cases were further analyzed (Table 1). The 140 cases
were stratified into three groups based on relative miR-
133b expression (tumor/non-tumor ratio) using tertiles:
miR-133b low expression (tumor/non-tumor ratio < 0.24,
n = 46), miR-133b moderate expression (tumor/non-
tumor ratio 0.24–0.87, n = 47) and miR-133b high
expression (tumor/non-tumor ratio > 0.87, n = 47). The
miR-133b expression levels were negatively correlated to
lymph node metastasis in these patients, with the
miR-133b low-expression group exhibiting a signifi-
cantly higher rate of lymph node metastasis rate compared
with moderate- or high-expression groups (p = 0.03). And
miR-133b expression levels also showed negative relation-
ship with age. However, miR-133b expression levels did
not show any relationship with gender, tumor differen-
tiation, tumor location, tumor local invasion or TNM
stage (Table 1).Overexpression of miR-133b inhibits metastasis of GC cell
in vitro
The negative relationship between miR-133b and lymph
node metastasis of GC aroused interest in the role of
miR-133b in the metastasis of GC cells. The expression
of miR-133b was the lowest in MKN-28 and SGC-7901
cells, so we selected these two cell lines as models to
investigate metastasis in vitro. Synthetic miR-133b mimic
and negative control mimic (NC) were transfected into
MKN-28 or SGC-7901 cells respectively. The ectopic ex-
pression of miR-133b in cells was confirmed by qRT-PCR
(Additional file 1: Figure S1).
As shown in Figure 2A, cell migratory ability was
significantly inhibited in MKN-28 cells transfected with
miR-133b mimic. The ability of MKN-28 cells to migrate
through an insert membrane was also significantly inhib-
ited by miR-133b (Figure 2B), and cell invasion through
the extracellular matrix gel was also reduced by miR-
133b (Figure 2C). Similar results were observed in
SGC-7901 cells (Additional file 2: Figure S2). Results
Table 1 Relationship between expression levels of miR-











≤60 20 16 28 *0.04
>60 26 31 19
Gender
Male 39 30 31 0.05
Female 7 17 16
Differentiation
High, middle 14 17 9 0.18
Low 32 30 38
Location
Distal third 28 23 24 0.63
Middle third 13 14 16
Proximal third 5 10 7
Local invasion
T1 5 6 1 0.16
T2 14 5 12
T3 10 14 13
T4 17 22 21
Lymph node
metastasis
N0 7 12 13 *0.03
N1 7 7 11
N2 14 19 19
N3 18 9 4
TNM stage
I, II 22 20 22 0.86
III, IV 24 27 25
A total of 140 cases were stratified into three groups based on relative
miR-133b expression (tumor/non-tumor ratio) using tertiles: miR-133b low
expression (tumor/non-tumor ratio < 0.24, n = 46), miR-133b moderate
expression (tumor/non-tumor ratio 0.24–0.87, n = 47) and miR-133b high
expression (tumor/non-tumor ratio > 0.87, n = 47). The relationship between
the miR-133b expression levels and clinicopathologic parameters was analyzed
using the Pearson Chi-square test. *, p <0.05.
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in vitro by overexpression of miR-133b.
Overexpression of miR-133b inhibits peritoneal spreading
of GC cells in vivo
Given that miR-133b inhibited metastasis of GC cells
in vitro, we further tested whether miR-133b could affect
tumor metastasis in vivo. MKN-28 cells, RV-miR-133b
(MKN-28 cells with retrovirus-mediated miR-133b stable
expression) or RV-miR-NC (MKN-28 cells with the empty
vector) were obtained as described in the Methods
section. After miR-133b expression in the stable cell lineswas confirmed by qRT-PCR (Additional file 3: Figure S3),
cells were intraperitoneally injected into 4-week-old male
nude mice. The mice were euthanized two months after
the injection, and the tumor lesions in the peritoneal
cavity were counted. The number of peritoneal nodules
was significantly less in mice injected with RV-miR-133b
cells than in the MKN-28 group or RV-miR-NC group
(Figure 3). Thus, these results indicate that miR-133b
could suppress metastasis of GC cells in vivo.
Gli1 is a target gene of miR-133b
To identify how miR-133b functions in GC cells, com-
putational prediction of miR-133b targets was perfor-
med. We used the online search tools miRNAMap 2.0
[25], which employs miRanda [26], TargetScan [27] and
RNAhybrid [28], as computational tools. Among the
hundreds of candidate genes predicted by both of
miRanda and RNAhybrid, the transcription factor Gli1
was of particular interest. Gli1 has been reported as
highly expressed in GC and positively correlated with
lymph node metastasis [29,30]. Furthermore, a previous
study showed that Gli1 siRNA reduced GC cell migra-
tion and invasion, possibly through SIP1 [31] or PI3K/
Akt pathway [30].
Luciferase reporter assays were performed to verify a
possible direct interaction between miR-133b and the 3′
UTR of Gli1. Luciferase reporters were constructed
containing either wild-type full-length Gli1 3′UTR
(pMIR/Gli1) or a mutated Gli1 3′UTR (pMIR/Gli1/mut,
in which the sequence of the putative miR-133b binding
site was mutated) (Figure 4A). The pMIR/Gli1 and pMIR/
Gli1/mut luciferase reporter constructs were transfected
into MKN-28 cells along with miR-133b or negative con-
trol mimic. The relative luciferase activity of the pMIR/
Gli1 reporter was markedly suppressed by 45.6% (p < 0.01)
compared with that of pMIR/Gli1/mut in a miR-133b-
dependent manner (Figure 4B). This result strongly indi-
cates that the 3′UTR of Gli1 harbors a direct binding sites
for miR-133b.
To examine whether miR-133b affects Gli1 at mRNA
level or protein level, Gli1 expression was examined by
qRT-PCR and western blot. As shown in Figure 4C,
miR-133b mimic had no effect on Gli1 mRNA level.
However, Gli1 protein level was decreased in miR-133b
mimic-transfected MKN-28 cells as shown in Figure 4C.
These results strongly suggest that miR-133b negatively
regulates Gli1 expression through translation repression
rather than mRNA degradation.
Among the genes reported to promote the metastasis
of GC [32-34], Zeb2 and OPN are direct transcriptional
targets of Gli1 [35,36]. As shown in Figure 4E and F, the
mRNA levels of Zeb2 and OPN were both markedly
reduced in MKN-28 cells transfected with miR-133b
mimic. Protein levels of Zeb2 and OPN also were markedly
Figure 2 MiR-133b inhibits metastasis of GC cells in vitro. Representative images of scratch assays (A), migration assays (B) and invasion
assays (C) of MKN-28 cells, MKN-28 cells transfected with miR-133b mimic or negative control mimic (NC) (left panels). Relevant quantification of
the results is shown in the bar graphs (right panels). The results are mean of three independent experiments ± S.D. *, p <0.05.
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mimic (Figure 4D).
Discussion
Several findings have linked miRNAs to GC. MiR-133b,
located in chromosome 6, was predicted based on
comparative analysis of human, mouse and Fugu [37],
and experimentally verified by sequencing in 2007 [38].
Although miR-133b was originally suggested to be solely
expressed in skeletal muscle [14], it was suggested to act
as a tumor-suppressor in many types of cancers recently
[15-22]. In this study, we found that miR-133b was fre-
quently decreased in the tumor tissues of GC patients,Figure 3 MiR-133b inhibits peritoneal spreading in nude mice. (A) Rep
(B) Quantification of the peritoneal nodules is shown in the bar graph. Theas well as in cultured GC cell lines, which is consistent
with another group’s finding from miRNA microarray
data in three GC patient tissues [13]. Importantly,
miR-133b levels were negatively correlated with lymph
node metastasis of gastric cancer in the 140 cases,
which is consist with Wu’s finding in 15 lymph node
negative GC tissues compare with 15 lymph node positive
GC tissues [39].
Given that miR-133b was downregulated in GC tissues
and negatively correlated with lymph node metastasis of
GC, we speculated that overexpression of miR-133b
might suppress metastasis of GC cells. Restoration of
miR-133b in MKN-28 and SGC-7901 cells significantlyresentative images of nude mice injected with indicated cells.
results are mean of 6–10 mice ± SD. *, p <0.05.
Figure 4 MiR-133b direct targets Gli1 in GC cells. (A) Sequence of the Gli1 3′UTR showing the miR-133b binding seed region and mutation of
the Gli1 3′UTR seed region to create Gli1-mut. (B) Luciferase activities of the reporter containing wild-type Gli1 3′UTR or mutant Gli1 3′UTR are
shown in the bar graph. (C) Relative mRNA levels of Gli1 in indicated cells analyzed by qRT-PCR is shown in the bar graph. (D) Representative
western blot images of indicated protein in MKN-28 cells (left panels), with relevant quantification (right panel). Relative mRNA levels of Zeb2
(E) and OPN (F) in indicated cells analyzed by qRT-PCR are shown in the bar graph. The results are the mean of three independent experiments ± S.D.
*, p <0.05.
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strongly suggested an inhibitory role of miR-133b in
metastasis of GC, which is a novel finding. These results
also strongly demonstrated that the decreased miR-133b
expression in GC should be a factor contributing to the
development of GC rather than being a consequence of
GC. Therefore, the significant inhibition of peritoneal
spreading in nude mice implies that therapeutic strategies
of introducing miR-133b into cancer cells might be useful
for slowing the process of tumorigenesis.
Identifying miRNA targets that are essential for cancer
development and metastasis may help elucidate their
mechanisms of action and the patheways that miRNAs
modulate [40]. Using bioinformatic algorithms, we iden-
tified Gli1 as a possible direct target gene for miR-133b.
Gli1 was initially found as an amplified gene in a malig-
nant glioma [41]. It is a strong positive activator of
downstream target genes and is a transcriptional target
of Hedgehog signaling [42]. Gli1 can also be upregulated
by RAS/PKC [43], TGFβ [44] and PI3K [45], and down-
regulated by PKA [45] and p53 [46]. Gli1 expression in
epithelial cells can induce cell transformation character-
ized by anchorage-independent proliferation [47]. It has
also been reported as a metastatic oncogene [36,48,49].
Increasing number of studies show that expression of
Gli1 is upregulated in GC [50-52]. We validated this
suggestion with luciferase reporter assays. MiR-133b
directly suppressed expression of Gli1 in MKN-28 cells,
which occurred through translation repression rather
than mRNA degradation. Furthermore, the expression
levels of Gli1 downstream target genes Zeb2 and OPN
[35,36] were decreased. Zeb2 and OPN were reported to
promote the metastasis of GC [32-34]. This suggests
that GC cell metastasis inhibition induced by miR-133b
might be partially related to its suppression of Zeb2 and
OPN expression, which occurs via direct interaction
with the Gli1 3′UTR. Taken as a whole, these data indi-
cate that miR-133b suppresses GC metastasis at least
partially through direct interaction with the Gli1 3′UTR.
In addition to our finding, Wen et al. reported that
miR-133b could inhibit GC cell proliferation and colony
formation in vitro by direct targeting FGFR1 [53]. It is
likely that as a novel tumor suppressor, miR-133b has
multiple targets and functions in GC tumor cells. Further
studies are needed to fully understand the role of
miR-133b in tumor metastasis.
Conclusions
In summary, miR-133b is frequently decreased in human
gastric cancer. Restoration of miR-133b inhibits GC
metastasis, at least partly by directly suppressing the ex-
pression of Gli1. Such roles for miR-133b in GC suggest
its potential as a therapeutic microRNA for GC treatment,
which is worth further investigation.Additional files
Additional file 1: Figure S1. MiR-133b mimic significantly enhanced
miR-133b level in MKN-28 and SGC-7901 cells. Relative levels of miR-133b
in MKN-28 (A) and SGC-7901 cells (B) were analyzed by qRT-PCR and
shown in the bar graph. The results are the mean of three independent
experiments ± S.D. ***, p < 0.001.
Additional file 2: Figure S2. MiR-133b inhibits metastasis of SGC-7901
cells in vitro. Representative images of scratch assays (A), migration assays
(B) and invasion assays (C) of SGC-7901 cells,SGC-7901 cells transfected
with the miR-133b mimic or negative control mimic (NC) (left panels).
Relevant quantification is shown in bar graphs (right panels). The results
are the means of three independent experiments ± S.D. *, p < 0.05.
Additional file 3: Figure S3. Expression of miR-133b in stable cell lines.
Relative levels of miR-133b in MKN-28, RV-miR-NC and RV-miR-133b cells
were analyzed by qRT-PCR and shown in the bar graph. The results are
the means of three independent experiments ± S.D. ***, p < 0.001.Abbreviations
miRNA: MicroRNA; GC: Gastric cancer; 3′UTR: 3′-untranslated regions;
qRT-PCR: Quantitative real-time PCR.
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